Trial Profile
A Safety, Tolerability, Pharmacokinetics and Efficacy Study of ro7049389 in: (1) Single- (With or Without Food) and Multiple- (With Midazolam) Ascending Doses in Healthy Volunteers; (2) Patients Chronically Infected With Hepatitis b Virus (3) Patients With Chronic Hepatitis B
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 11 Jul 2022
Price :
$35
*
At a glance
- Drugs Linvencorvir (Primary) ; Midazolam
- Indications Hepatitis B
- Focus Adverse reactions; First in man; Pharmacodynamics; Pharmacokinetics; Therapeutic Use
- Sponsors Roche
- 07 Jul 2022 Status changed from active, no longer recruiting to completed.
- 26 Jun 2022 Results assessing HBV antigens reduction in chronic hepatitis B patients , presented at The International Liver Congress 2022.
- 26 Jun 2022 Antiviral and safety results following 48 weeks of RO7049389 plus NUC with/without Peg-IFN-alpha and 24 weeks of follow-up presented at The International Liver Congress 2022